Replimune (REPL) stock plunged 60% pre-market after the FDA rejected its melanoma drug RP1 for a second time. Jefferies downgraded the stock to 'Hold' and slashed its price target by 85% to $2. JPMorgan also downgraded to 'Underweight', warning of a difficult path forward and potential job cuts.